WAVE Life Sciences Revenue and Competitors
Estimated Revenue & Valuation
- WAVE Life Sciences's estimated annual revenue is currently $46.7M per year.
- WAVE Life Sciences received $93.4M in venture funding in April 2017.
- WAVE Life Sciences's estimated revenue per employee is $155,000
- WAVE Life Sciences's total funding is $174M.
- WAVE Life Sciences has 301 Employees.
- WAVE Life Sciences grew their employee count by 5% last year.
WAVE Life Sciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is WAVE Life Sciences?
Wave Life Sciences Ltd. (NASDAQ: WVE) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the unique versatility of its chemistry platform, Wave's pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
WAVE Life Sciences News
WaVe Life Sciences, a Boston, MA- and Japan-based provider of nucleic acid therapeutics, raised $18m in Series A funding. The round was led by RA Capital Management LLC and Kagoshima Shinsangyo Sosei Investment LP with participation from founding investor SNBL Ltd. In conjunction with the finan ...
Wave Life Sciences, a Boston, MA-based genetic medicine company, completed an oversubscribed $66m Series B financing. The round was led by new investor Foresite Capital with participation from new investors Fidelity Management and Research Company, New Leaf Venture Partners, Redmile Group, Jenn ...
Wave, a Harvard spinout, is using synthetic chemistry to develop a pipeline of nucleic acid therapeutics – developing stereopure treatments for Huntington’s disease and Duchenne muscular dystrophy that are expected to enter clinical development in 2016 and 2017, respectively. [Image courtesy of ...
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines ...
06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering ...
Wave Life Sciences (NASDAQ:WVE) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
WAVE Life Sciences Funding
|2015-02-03||$18.0M||A||RA Capital Management LLC||Article|